Red-flag symptom clusters in transthyretin familial amyloid polyneuropathy

Journal of the Peripheral Nervous System

Volumn 21, Issue 1, 2016, Pages 5-9

  Conceição, Isabel ^a   González Duarte, Alejandra ^b   Obici, Laura ^c   Schmidt, Hartmut H J ^d   Simoneau, Damien ^e   Ong, Moh Lim ^e   Amass, Leslie ^e  

^a HOSPITAL DE SANTA MARIA   (Portugal)

^b INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^d UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^e PFIZER INC   (United States)

Author keywords

diagnosis; hereditary amyloidosis; transthyretin; transthyretin familial amyloid neuropathy

Indexed keywords

AMYLOID NEUROPATHY; AUTONOMIC DYSFUNCTION; CARPAL TUNNEL SYNDROME; CLINICAL FEATURE; DIAGNOSTIC ERROR; DIAGNOSTIC TEST; EYE DISEASE; GASTROINTESTINAL SYMPTOM; GENETIC ASSOCIATION; GENOTYPE; HEART VENTRICLE HYPERTROPHY; HUMAN; KIDNEY FAILURE; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SENSORIMOTOR NEUROPATHY; TRANSTHYRETIN FAMILIAL AMYLOID POLYNEUROPATHY; WEIGHT REDUCTION; AMYLOID NEUROPATHIES, FAMILIAL; EARLY DIAGNOSIS;

AMYLOID NEUROPATHIES, FAMILIAL; EARLY DIAGNOSIS; HUMANS;

EID: 84961184868     PISSN: 10859489     EISSN: 15298027     Source Type: Journal    
DOI: 10.1111/jns.12153     Document Type: Review

References (22)

1. Adams D, Théaudin M, Cauquil C, Algalarrondo V, Slama M, (2014). FAP neuropathy and emerging treatments. Curr Neurol Neurosci Rep 14: 435.
2. Ando Y, Coelho T, Berk JL, Cruz MW, Ericzon BG, Ikeda S, Lewis WD, Obici L, Planté-Bordeneuve V, Rapezzi C, Said G, Salvi F, (2013). Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis 8: 31.
3. Andrade C, (1952). A peculiar form of peripheral neuropathy: familiar atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain 75: 408-427.
4. Bergström J, Gustavsson A, Hellman U, Sletten K, Murphy CL, Weiss DT, Solomon A, Olofsson BO, Westermark P, (2005). Amyloid deposits in transthyretin-derived amyloidosis: cleaved transthyretin is associated with distinct amyloid morphology. J Pathol 206: 224-232.
5. Briani C, Cavallaro T, Ferrari S, Taioli F, Calamelli S, Verga L, Adami F, Fabrizi GM, (2012). Sporadic transthyretin amyloidosis with a novel TTR gene mutation misdiagnosed as primary amyloidosis. J Neurol 259: 2226-2228.
6. Coelho T, Maia LF, da Silva AM, Cruz MW, Planté-Bordeneuve V, Suhr OB, Conceição I, Schmidt HH, Trigo P, Kelly JW, Labaudiniere R, Chan J, Packman J, Grogan DR, (2013). Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol 260: 2802-2814.
7. Conceição I, De Carvalho M, (2007). Clinical variability in type I familial amyloid polyneuropathy (Val30Met): comparison between late- and early-onset cases in Portugal. Muscle Nerve 35: 116-118.
8. Coutinho P, da Silva AM, Lima JL, Barbosa AR, (1980). Forty years of experience with type I amyloid neuropathy. Review of 483 cases. Amyloid and Amyloidosis., Glenner GG, Costa PP, de Freitas F,. Excerpta Medica, Amsterdam, 88-98.
9. Cowan AJ, Skinner M, Berk JL, Sloan JM, O'Hara C, Seldin DC, Sanchorawala V, (2011). Macroglossia-not always AL amyloidosis. Amyloid 18: 83-86.
10. Dohrn MF, Röcken C, De Bleecker JL, Martin JJ, Vorgerd M, Van den Bergh PY, Ferbert A, Hinderhofer K, Schröder JM, Weis J, Schulz JB, Claeys KG, (2013). Diagnostic hallmarks and pitfalls in late-onset progressive transthyretin-related amyloid-neuropathy. J Neurol 260: 3093-3108.
11. Ericzon BG, Wilczek HE, Larsson M, Wijayatunga P, Stangou A, Pena JR, Furtado E, Barroso E, Daniel J, Samuel D, Adam R, Karam V, Poterucha J, Lewis D, Ferraz-Neto BH, Cruz MW, Munar-Ques M, Fabregat J, Ikeda S, Ando Y, Heaton N, Otto G, Suhr O, (2015). Liver transplantation for hereditary transthyretin amyloidosis: after 20 years still the best therapeutic alternative? Transplantation 99: 1847-1854.
12. González-Duarte A, Lem-Carrillo M, Cárdenas-Soto K, (2013). Description of transthyretin S50A, S52P and G47A mutations in familial amyloidosis polyneuropathy. Amyloid 20: 221-225.
13. Ihse E, Rapezzi C, Merlini G, Benson MD, Ando Y, Suhr OB, Ikeda S, Lavatelli F, Obici L, Quarta CC, Leone O, Jono H, Ueda M, Lorenzini M, Liepnieks J, Ohshima T, Tasaki M, Yamashita T, Westermark P, (2013). Amyloid fibrils containing fragmented ATTR may be the standard fibril composition in ATTR amyloidosis. Amyloid 20: 142-150.
14. Koike H, Misu K, Ikeda S, Ando Y, Nakazato M, Ando E, Yamamoto M, Hattori N, Sobue G, (2002). Type I (transthyretin Met30) familial amyloid polyneuropathy in Japan: early- vs late-onset form. Arch Neurol 59: 1771-1776.
15. Koike H, Misu K, Sugiura M, Iijima M, Mori K, Yamamoto M, Hattori N, Mukai E, Ando Y, Ikeda S, Sobue G, (2004). Pathology of early- vs late-onset TTR Met30 familial amyloid polyneuropathy. Neurology 63: 129-138.
16. Koike H, Hashimoto R, Tomita M, Kawagashira Y, Iijima M, Tanaka F, Sobue G, (2011). Diagnosis of sporadic transthyretin Val30Met familial amyloid polyneuropathy: a practical analysis. Amyloid 18: 53-62.
17. Mead S, Reilly MM, (2015). A new prion disease: relationship with central and peripheral amyloidoses. Nat Rev Neurol 11: 90-97.
18. Planté-Bordeneuve V, Lalu T, Misrahi M, Reilly MM, Adams D, Lacroix C, Said G, (1998). Genotypic-phenotypic variations in a series of 65 patients with familial amyloid polyneuropathy. Neurology 51: 708-714.
19. Planté-Bordeneuve V, Ferreira A, Lalu T, Zaros C, Lacroix C, Adams D, Said G, (2007). Diagnostic pitfalls in sporadic transthyretin familial amyloid polyneuropathy (TTR-FAP). Neurology 69: 693-698.
20. Planté-Bordeneuve V, (2014). Update in the diagnosis and management of transthyretin familial amyloid polyneuropathy. J Neurol 261: 1227-1233.
21. Rowczenio DM, Noor I, Gillmore JD, Lachmann HJ, Whelan C, Hawkins PN, Obici L, Westermark P, Grateau G, Wechalekar AD, (2014). Online registry for mutations in hereditary amyloidosis including nomenclature recommendations. Hum Mutat 35: E2403-E2412.
22. Sekijima Y, (2015). Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments. J Neurol Neurosurg Psychiatry 86: 1036-1043.